Abstract: The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

Abstract: The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a tachykinin receptor antagonist, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a tachykinin receptor antagonist. The invention also relates to methods of preparing such compositions.

Abstract: Chemical conjugates which comprise an oligopeptide covalently bonded, either directly or through a chemical linker, to a peptide or small molecule that binds to an anti-apoptotic Bcl-2 family protein, inhibits the expression of the Bcl-2 family protein, or inhibits the function of the Bcl-2 family protein. Such a peptide or small molecule that binds to an anti-apoptotic Bcl-2 family protein, inhibits the expression of the Bcl-2 family protein, or inhibits the function of the Bcl-2 family protein may be conveniently referred to as a therapeutic agent. The oligopeptides are chosen from oligomers that are selectively recognized by the free prostate specific antigen (PSA) and are capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen.

Abstract: The present invention relates to methods of treating cancer using a combination of a PSA conjugate and radiation therapy. The methods of this invention comprise administering to a mammal in need amounts of at least one PSA conjugate, in combination with radiation therapy, either sequentially or concomitantly.

Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).

Abstract: The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis. The invention also relates to methods of preparing such compositions.

Abstract: Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent are described. Methods of treating benign prostate hypertrophy are also disclosed.

Abstract: Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

Abstract: Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).

Abstract: Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

Abstract: Assays which comprise oligopeptides and which are useful for determining free PSA protease activity in vitro and in vivo are described. Such oligopeptides comprise amino acid sequences that are recognized and proteolytically cleaved by free prostrate specific antigen (PSA). Also described are assays useful in identifying inhibitors of free PSA.

Abstract: A track compensator for adjusting tension of an endless track on a track-laying vehicle and for absorbing changes in track tension during vehicle operation. A tension adjuster, connected to an idler wheel, adjusts the distance between a drive wheel, at one end of the track, and the idler wheel at the other end of the track. A shock absorber mounted between the vehicle and the tension adjuster absorbs stress on the track caused by debris between the track and vehicle wheels.

Abstract: A casing for hydraulic lifts and the like of the type buried in the ground. The part of the casing deeply buried in the ground may be subject to corrosion and electrolysis, which is quite common in many soils, and is made from a strong, fiberglas composite material. The part of the casing not subject to corrosion is metallic. Flanges connect the two parts in end-to-end sealed relation with respect to each other and the seals and guides for the plunger are carried in the metallic part of the casing. A non-metallic bulkhead is bonded to the bottom of the fiberglas composite casing and may have a port opening through its bottom wherein the lift is a semi-hydraulic lift as is common with passenger car lifts.

Abstract: An adjustable pad hydraulic lift structure has a vehicle engaging and supporting pad vertically movable by a hydraulic piston, the pad being mounted on a bolster and having load transfer blocks facing downwardly for engagement with the bolster to transfer vehicle load from the pad to the bolster. Supporting and guide rods on the bolster and bearings on the pad cooperate to support the unloaded pad for adjustment into selected position over the bolster, and while supporting the unloaded pad maintaining the pad at an elevation wherein the load transfer blocks are supported free of the bolster to permit free adjustments of the pad. The supporting and guide rods are yieldable when the pad is under vehicle load to permit the load transfer blocks to engage the bolster for load transfer from the pad to the bolster.